Nutraceuticals, a blend of the words “nutrition” and “pharmaceuticals”, have proven to be a significant ally in the ever-changing field of health and wellness. These functional foods and dietary supplements, derived from natural food sources, provide more than just basic nutritional benefits. The wide range of nutraceuticals includes insoluble and soluble dietary fibres, probiotics, polyunsaturated fatty acids (PUFAs), antioxidant vitamins, polyphenols as well as various spices and herbs to cater to different health needs. Nutraceutical quality control involves a multi-step approach to the te ..read more

Innovent Biologics has unveiled Phase III (DREAMS-2) results for mazdutide, indicating superiority over dulaglutide in glycaemic control for type 2 diabetes (T2D) patients in China. “With its potential to revolutionise T2D treatment, mazdutide’s success could not only reshape the landscape of diabetes therapeutics in China but also underscores the growing demand for innovative solutions amidst the escalating prevalence of T2D in the region,” says GlobalData. Mazdutide is reportedly the only glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist to reach Phase III ..read more

Biocon  announced the signing of an exclusive licensing and supply agreement with Handok, a pharma company in South Korea, for the commercialisation of its vertically integrated, complex drug product, Synthetic Liraglutide.  Liraglutide is an injection in a pre-filled pen, used in the treatment of chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity.  Under the terms of this agreement Biocon will undertake the development, manufacturing and supply of the drug product, and Handok will be responsible for obtaining regulatory approval a ..read more

 Sun Pharmaceutical Industries and Taro Pharmaceutical Industries, announced that the merger agreement between Taro and Sun Pharma was approved  by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro  shareholders unaffiliated with Sun Pharma) at an Extraordinary General Meeting and an Ordinary Class  Meeting on May 22, 2024. The details of the merger agreement were announced on January 17, 2024.   Dilip Shanghvi, Managing Director of Sun Pharma, said, “We are pleased with the approval by Taro’s  shareholders, w ..read more

Gerresheimer Glas GmbH, an indirect subsidiary of Gerresheimer AG, has signed a purchase agreement with funds advised by Triton for the acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group (Bormioli Pharma). The purchase price is based on a determined enterprise value of around EUR 800 million, which corresponds to an adj. EBITDA multiple of around 10 Bormioli Pharma, has 9 production sites in Europe. The Group generates revenues of around EUR 370 million and an adj. EBITDA margin of around 21 per cent. Bormioli Pharma has a complementary portfolio of pharmaceutic ..read more

Emcure Pharmaceuticals and its biotech subsidiary, Gennova Biopharmaceuticals have amicably resolved all legal disputes with HDT Bio Corporation. The litigation between them, including before US courts and the arbitral tribunal in London, has been settled and dismissed. Gennova and HDT, who previously collaborated on the successful development of Gennova’s mRNA Covid-19 vaccines, will once again collaborate on the development and commercialisation of mRNA vaccines.  The parties have entered into a long-term agreement to develop mRNA vaccines against a broad range ..read more

PharmaLytica Expo, the flagship event within South India’s pharmaceutical industry, is scheduled from May 30 to June, 2024, at HITEX, Hyderabad. Organised by Informa Markets in India, this event marksits 10th edition, providing a business platform for showcasing the latest industry trends, innovations, and business opportunities across Pharma Machinery & Packaging, Lab Analytical & Cleanroom, and Pharma Ingredients segments. PharmaLytica 2024 anticipates the participation of more than 200 exhibitors showcasing more than 1000 brands from across the country, including companies like, Sc ..read more

Indoco Remedies announced the receipt of final approval from the  United States Food and Drug Administration (USFDA for Abbreviated New Drug Application (ANDA) for Pregabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, and 300mg. This is a generic equivalent of the Reference Listed Drug, Lyrica Capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, and 300 mg, of Upjohn US  LLC. This product, Pregabalin capsules, will be manufactured by Indoco Remedies, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa – 403722 in India. Pregabalin is used ..read more

Alvotech and Dr Reddy’s Laboratories SA, a wholly-owned subsidiary of Dr Reddy’s Laboratories have entered into a license and supply agreement for the commercialisation of AVT03, Alvotech’s biosimilar candidate to Prolia and Xgeva (denosumab). The collaboration combines Dr Reddy’s global commercial presence with Alvotech’s proven capabilities in developing biosimilars for markets worldwide.  Alvotech will be responsible for development and manufacturing of the product. Dr Reddy’s will be responsible for registration and commercialisation of the product in the applicable markets. The lice ..read more

Biocon Biologics, announced that the U.S. Food and Drug Administration (US FDA) has approved the company’s first-to-file application for Yesafili (aflibercept-jbvf), an interchangeable* biosimilar aflibercept. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA (aflibercept). YESAFILI is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central ..read more